首页> 美国卫生研究院文献>BMC Cancer >Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized non-comparative phase II SCARCE GERCOR trial

【2h】

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized non-comparative phase II SCARCE GERCOR trial

机译：Atezolizumab联合改良多西他赛-顺铂-5-氟尿嘧啶（mDCF）方案与mDCF在转移性或不可切除的局部晚期复发性肛门鳞状细胞癌患者中的比较：一项随机非对照II期SCARCE GERCOR试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Main inclusion and exclusion criteria of the trial

机译：试验的主要纳入和排除标准

著录项

期刊名称 BMC Cancer
作者
Stefano Kim; Bruno Buecher; Thierry André; Marine Jary; François-Clément Bidard; François Ghiringhelli; Éric François; Julien Taieb; Denis Smith; Christelle de la Fouchardière; Jérôme Desramé; Emmanuelle Samalin; Aurélie Parzy; Nabil Baba-Hamed; Olivier Bouché; David Tougeron; Laëtitia Dahan; Farid El Hajbi; Marion Jacquin; Magali Rebucci-Peixoto; Laurie Spehner; Véronique Vendrely; Dewi Vernerey; Christophe Borg;
展开▼
作者单位

展开▼
年(卷),期 2020(20),-1
年度 2020
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Anal carcinoma; Advanced; Atezolizumab; Chemotherapy; Immunotherapy; Docetaxel;

机译：肛门癌;晚期;Atezolizumab;化学疗法;免疫疗法;多西他赛;

相似文献

外文文献
中文文献
专利

1. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial [J] . Stefano Kim, Bruno Buecher, Thierry André, BMC Cancer . 2020,第1期

机译：atezolizumab加修饰的多西紫杉醇 - 顺铂-5-氟尿嘧啶（MDCF）方案与MDCF在转移或不可切除的局部晚期复发性肛鳞细胞癌中的患者：随机的非比较期II稀缺的Gercor试验
2. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial [J] . Ochenduszko Sebastian, Puskulluoglu Miroslawa, Konopka Kamil, Medical oncology . 2015,第10期

机译：一线姑息化疗联合EOX和mDCF方案对局部晚期无法手术或转移性HER2阴性胃或胃食管交界性腺癌患者的疗效和安全性比较：一项3期随机研究
3. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. [J] . Schoffski P, Catimel G, Planting AS, Annals of oncology: official journal of the European Society for Medical Oncology . 1999,第1期

机译：多西紫杉醇和顺铂：在局部晚期，复发或转移性头颈部鳞状细胞癌患者中的有效方案。 EORTC早期临床研究小组II期研究的结果。
4. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial [O] . Sebastian Ochenduszko, Miroslawa Puskulluoglu, Kamil Konopka, -1

机译：一线姑息化疗联合EOX和mDCF方案对局部晚期无法手术或转移性HER2阴性胃或胃食管交界性腺癌患者的疗效和安全性比较：一项3期随机研究
5. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial [O] . Sebastian Ochenduszko, Miroslawa Puskulluoglu, Kamil Konopka, 2015

机译：一线姑息化疗联合EOX和mDCF方案对局部晚期无法手术或转移性HER2阴性胃或胃食管交界性腺癌患者的疗效和安全性比较：一项3期随机研究

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized non-comparative phase II SCARCE GERCOR trial

摘要

著录项

相似文献

相关主题

期刊订阅